Kynam Capital Management
Latest statistics and disclosures from Kynam Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are SNDX, CLDX, PCVX, COGT, VERA, and represent 51.52% of Kynam Capital Management's stock portfolio.
- Added to shares of these 10 stocks: TVTX (+$57M), URGN (+$40M), LEGN (+$29M), CTMX (+$28M), RVMD (+$20M), SLNO (+$19M), VRDN (+$17M), EVMN (+$10M), STRO (+$9.8M), BEAM (+$7.3M).
- Started 5 new stock positions in CADL, URGN, SLNO, LEGN, RVMD.
- Reduced shares in these 10 stocks: COGT (-$82M), TYRA (-$41M), CGON (-$39M), BCRX (-$35M), DVAX (-$21M), NRIX (-$12M), WVE (-$8.7M), OMER, APLS, CLDX.
- Sold out of its positions in CGON, DVAX, OMER, TYRA.
- Kynam Capital Management was a net buyer of stock by $37k.
- Kynam Capital Management has $1.6B in assets under management (AUM), dropping by 3.56%.
- Central Index Key (CIK): 0001907884
Tip: Access up to 7 years of quarterly data
Positions held by Kynam Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csvPortfolio Holdings for Kynam Capital Management
Kynam Capital Management holds 37 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Syndax Pharmaceuticals (SNDX) | 11.6 | $188M | 8.1M | 23.36 |
|
|
| Celldex Therapeutics Com New (CLDX) | 11.4 | $185M | 5.8M | 31.72 |
|
|
| Vaxcyte (PCVX) | 10.5 | $170M | 2.9M | 58.11 |
|
|
| Cogent Biosciences (COGT) | 9.6 | $155M | -34% | 4.0M | 38.49 |
|
| Vera Therapeutics Cl A (VERA) | 8.4 | $137M | 3.4M | 40.23 |
|
|
| Beam Therapeutics (BEAM) | 5.4 | $88M | +9% | 3.7M | 23.83 |
|
| Travere Therapeutics (TVTX) | 4.4 | $72M | +368% | 2.4M | 29.71 |
|
| Cytomx Therapeutics (CTMX) | 4.4 | $71M | +67% | 15M | 4.70 |
|
| BioCryst Pharmaceuticals (BCRX) | 3.3 | $54M | -39% | 5.7M | 9.52 |
|
| Miragen Therapeutics (VRDN) | 2.8 | $46M | +59% | 2.3M | 19.56 |
|
| Cullinan Oncology (CGEM) | 2.7 | $44M | 3.1M | 14.21 |
|
|
| Urogen Pharma (URGN) | 2.5 | $40M | NEW | 2.2M | 17.98 |
|
| Kalvista Pharmaceuticals (KALV) | 2.3 | $37M | 1.8M | 20.13 |
|
|
| Apellis Pharmaceuticals (APLS) | 2.0 | $33M | -9% | 825k | 40.23 |
|
| Legend Biotech Corp Sponsored Ads (LEGN) | 1.8 | $29M | NEW | 1.6M | 18.09 |
|
| Mbx Biosciences (MBX) | 1.7 | $28M | 935k | 29.85 |
|
|
| Immunocore Hldgs Ads (IMCR) | 1.6 | $27M | +3% | 885k | 30.15 |
|
| Sutro Biopharma Com Shs (STRO) | 1.3 | $22M | +81% | 873k | 24.91 |
|
| Revolution Medicines Put Option (RVMD) | 1.2 | $20M | NEW | 208k | 97.25 |
|
| Burning Rock Biotech Sponsored Ads (BNR) | 1.2 | $20M | +23% | 1.2M | 16.12 |
|
| Soleno Therapeutics (SLNO) | 1.2 | $19M | NEW | 560k | 33.48 |
|
| Nurix Therapeutics (NRIX) | 1.1 | $19M | -39% | 1.2M | 15.50 |
|
| Pharvaris N V (PHVS) | 1.1 | $18M | 640k | 28.25 |
|
|
| Evommune Com Shs (EVMN) | 0.9 | $14M | +237% | 626k | 22.99 |
|
| Relay Therapeutics (RLAY) | 0.9 | $14M | 1.4M | 9.95 |
|
|
| Geron Corporation (GERN) | 0.6 | $10M | +97% | 6.8M | 1.49 |
|
| Engene Holdings (ENGN) | 0.6 | $9.2M | -9% | 1.4M | 6.81 |
|
| Design Therapeutics (DSGN) | 0.5 | $8.3M | 785k | 10.64 |
|
|
| Wave Life Sciences SHS (WVE) | 0.4 | $7.0M | -55% | 965k | 7.25 |
|
| Eliem Therapeutics (CLYM) | 0.4 | $6.9M | -2% | 1.0M | 6.85 |
|
| Amarin Corp Sponsored Adr (AMRN) | 0.4 | $6.8M | +21% | 472k | 14.46 |
|
| Biohaven (BHVN) | 0.4 | $5.9M | 703k | 8.46 |
|
|
| Prelude Therapeutics (PRLD) | 0.3 | $5.4M | +101% | 1.6M | 3.42 |
|
| Caribou Biosciences (CRBU) | 0.3 | $4.8M | 2.5M | 1.90 |
|
|
| Alector (ALEC) | 0.3 | $4.3M | 2.0M | 2.15 |
|
|
| Proqr Thrapeutics N V Shs Euro (PRQR) | 0.2 | $2.5M | 1.6M | 1.62 |
|
|
| Candel Therapeutics (CADL) | 0.1 | $980k | NEW | 200k | 4.90 |
|
Past Filings by Kynam Capital Management
SEC 13F filings are viewable for Kynam Capital Management going back to 2021
- Kynam Capital Management 2026 Q1 filed May 15, 2026
- Kynam Capital Management 2025 Q4 filed Feb. 17, 2026
- Kynam Capital Management 2025 Q3 filed Nov. 14, 2025
- Kynam Capital Management 2025 Q2 filed Aug. 14, 2025
- Kynam Capital Management 2025 Q1 filed May 15, 2025
- Kynam Capital Management 2024 Q4 filed Feb. 14, 2025
- Kynam Capital Management 2024 Q3 filed Nov. 14, 2024
- Kynam Capital Management 2024 Q2 filed Aug. 14, 2024
- Kynam Capital Management 2024 Q1 filed May 15, 2024
- Kynam Capital Management 2023 Q4 filed Feb. 14, 2024
- Kynam Capital Management 2023 Q3 filed Nov. 14, 2023
- Kynam Capital Management 2023 Q2 filed Aug. 14, 2023
- Kynam Capital Management 2023 Q1 filed May 15, 2023
- Kynam Capital Management 2022 Q4 filed Feb. 14, 2023
- Kynam Capital Management 2022 Q3 filed Nov. 14, 2022
- Kynam Capital Management 2022 Q2 filed Aug. 15, 2022